Your browser doesn't support javascript.
loading
Tadalafil and patients preference in the treatment of erectile dysfunction / 中华男科学杂志
National Journal of Andrology ; (12): 1145-1148, 2006.
Artículo en Chino | WPRIM | ID: wpr-289060
ABSTRACT
ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
Asunto(s)
Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Inhibidores de Fosfodiesterasa / Psicología / Psicoterapia / Carbolinas / Satisfacción del Paciente / Usos Terapéuticos / Quimioterapia / Tadalafilo / Disfunción Eréctil Límite: Humanos / Masculino Idioma: Chino Revista: National Journal of Andrology Año: 2006 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Inhibidores de Fosfodiesterasa / Psicología / Psicoterapia / Carbolinas / Satisfacción del Paciente / Usos Terapéuticos / Quimioterapia / Tadalafilo / Disfunción Eréctil Límite: Humanos / Masculino Idioma: Chino Revista: National Journal of Andrology Año: 2006 Tipo del documento: Artículo